Prime Medicine, Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Deciphera Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc.

Relay Therapeutics, Inc.

Tango Therapeutics, Inc.

Protagonist Therapeutics, Inc.

Prime Medicine, Inc.

Arvinas, Inc.

Immatics NV

Rayzebio, Inc.

Replimune Group, Inc.

Pliant Therapeutics, Inc.

Why is Prime Medicine, Inc. ?

Flat results in Mar 26

NET SALES(HY) At USD 1.69 MM has Grown at -53.42%
ROCE(HY) Lowest at -216.07%
RAW MATERIAL COST(Y) Grown by 557.48% (YoY)

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 72.46%, its profits have fallen by -3.2%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Prime Medicine, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Prime Medicine, Inc.

72.46%

-0.65

96.51%

S&P 500

22.99%

1.78

12.93%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

54.04%

EBIT Growth (5y)

-182.65%

EBIT to Interest (avg)

-162.81

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.29

Sales to Capital Employed (avg)

0.03

Tax Ratio

0.07%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

66.30%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.05

EV to EBIT

-2.12

EV to EBITDA

-2.19

EV to Capital Employed

-9.05

EV to Sales

95.15

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-166.77%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company

NET PROFIT(HY)

Higher at USD -95.74 MM

DEBTORS TURNOVER RATIO(HY)

Highest at 474.59 times

-10What is not working for the Company

NET SALES(HY)

At USD 1.69 MM has Grown at -53.42%

ROCE(HY)

Lowest at -216.07%

RAW MATERIAL COST(Y)

Grown by 557.48% (YoY

Here's what is working for Prime Medicine, Inc.

Net Profit

Higher at USD -95.74 MM

than preceding 12 month period ended Mar 2026

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Debtors Turnover Ratio

Highest at 474.59 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Prime Medicine, Inc.

Net Sales

At USD 1.69 MM has Grown at -53.42%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (USD MM)

Raw Material Cost

Grown by 557.48% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales